The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Nafamostat mesilate decreases the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). However, no studies have administered nafamostat mesilate after ERCP. So we investigated if the infusion of nafamostat mesilate after ERCP can affect the post-ERCP pancreatitis (PEP) in high-risk patients.
In a tertiary hospit...
Alternative Titles
Full title
The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5df3752ada79448f8036b75d0318a7eb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5df3752ada79448f8036b75d0318a7eb
Other Identifiers
ISSN
1471-230X
E-ISSN
1471-230X
DOI
10.1186/s12876-022-02345-3
